AU2023204432A1 - Deuterated organic compounds and uses thereof - Google Patents

Deuterated organic compounds and uses thereof Download PDF

Info

Publication number
AU2023204432A1
AU2023204432A1 AU2023204432A AU2023204432A AU2023204432A1 AU 2023204432 A1 AU2023204432 A1 AU 2023204432A1 AU 2023204432 A AU2023204432 A AU 2023204432A AU 2023204432 A AU2023204432 A AU 2023204432A AU 2023204432 A1 AU2023204432 A1 AU 2023204432A1
Authority
AU
Australia
Prior art keywords
compound
disorder
formula
free
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023204432A
Other languages
English (en)
Inventor
David Garvey
Jordi SERRATS
Vikram SUDARSAN
Krishna VADODARIA
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engrail Therapeutics Inc
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of AU2023204432A1 publication Critical patent/AU2023204432A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023204432A 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof Pending AU2023204432A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263296134P 2022-01-03 2022-01-03
US63/296,134 2022-01-03
US202263345007P 2022-05-23 2022-05-23
US63/345,007 2022-05-23
US202263384992P 2022-11-25 2022-11-25
US63/384,992 2022-11-25
PCT/US2023/010050 WO2023130117A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
AU2023204432A1 true AU2023204432A1 (en) 2024-07-18

Family

ID=87000368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023204432A Pending AU2023204432A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Country Status (10)

Country Link
US (1) US20250091990A1 (https=)
EP (1) EP4460490A4 (https=)
JP (1) JP2025501410A (https=)
KR (1) KR20240132476A (https=)
AU (1) AU2023204432A1 (https=)
CA (1) CA3242751A1 (https=)
IL (1) IL314019A (https=)
MX (1) MX2024008372A (https=)
TW (1) TW202340145A (https=)
WO (1) WO2023130117A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333671A (zh) 2022-01-03 2023-09-01 美商恩格瑞爾療法公司 氘化有機化合物及其用途
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373288B1 (ko) * 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) * 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法

Also Published As

Publication number Publication date
WO2023130117A1 (en) 2023-07-06
TW202340145A (zh) 2023-10-16
US20250091990A1 (en) 2025-03-20
EP4460490A1 (en) 2024-11-13
JP2025501410A (ja) 2025-01-17
EP4460490A4 (en) 2026-03-18
CA3242751A1 (en) 2023-07-06
IL314019A (en) 2024-08-01
KR20240132476A (ko) 2024-09-03
MX2024008372A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
TWI888599B (zh) 取代哌啶化合物及其用途
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
US12606523B2 (en) Deuterated organic compounds and uses thereof
US20260098011A1 (en) Deuterated organic compounds and uses thereof
AU2017238858A1 (en) Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
JP5281395B2 (ja) 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
KR102150739B1 (ko) 카르바메이트/우레아 유도체
NO341760B1 (no) 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-piperazinyl]etyl]-2-(1-propynyl)-7Hpyrazolo-[ 4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin, eller et farmasøytisk akseptabelt salt derav, farmasøytiske preparater derav, samt dets anvendelse ved behandling av sentralnervesystemsykdommer.
US20250091990A1 (en) Deuterated organic compounds and uses thereof
AU2010328419A1 (en) 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
TWI644914B (zh) １，２，４－三唑并［４，３－ａ］吡啶化合物及其作為ＭＧＬＵＲ２受體之正向異位調節劑的用途
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
CN117957222A (zh) 毒蕈碱受体4拮抗剂及使用方法
CN118804910A (zh) 氘代有机化合物及其用途
CN118804746A (zh) 氘代有机化合物及其用途
JP2014524470A (ja) 神経型ニコチン性アセチルコリン受容体リガンドとしての１，４−ジアザビシクロ［３．２．２］ノナン
TWI922338B (zh) 取代哌啶化合物及其用途
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение
BR112016004412B1 (pt) Compostos de 1,2,4-triazolo[4,3-a]piridina como moduladores alostéricos positivos de recetores mglur2, composição farmacêutica e produto que os compreende